AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,714.00p
   
  • Change Today:
      14.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,667.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.66m
  • Volume: 151,814
  • Market Cap: £166,138m
  • RiskGrade: 123

Regulatory News

Fixed-duration Calquence approved in EU for 1L CLL 06-Jun-2025 07:00 RNS
Block listing Interim Review 02-Jun-2025 15:05 RNS
Total Voting Rights 02-Jun-2025 15:00 RNS
Imfinzi recommended in EU for bladder cancer 27-May-2025 07:00 RNS
Director/PDMR Shareholding 23-May-2025 10:00 RNS
Director Declaration 21-May-2025 13:45 RNS
Acquisition of EsoBiotec completed 20-May-2025 07:00 RNS
Imfinzi improved DFS in early bladder cancer 09-May-2025 07:00 RNS
Enhertu improved pCR in early-stage breast cancer 07-May-2025 07:30 RNS
Calquence combination approved in EU for 1L MCL 06-May-2025 07:00 RNS
Breztri met primary endpoints in Ph3 asthma trials 02-May-2025 07:00 RNS
Director/PDMR Shareholding 01-May-2025 16:00 RNS
Total Voting Rights 01-May-2025 15:00 RNS
Fixed-duration Calquence recommended in EU for CLL 29-Apr-2025 07:10 RNS
Update on CAPItello-280 Phase III trial 29-Apr-2025 07:05 RNS
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,714.00p
Change Today 14.00p
% Change 0.13 %
52 Week High 13,276.00
52 Week Low 9,667.00
Volume 151,814
Shares Issued 1,550.66m
Market Cap £166,138m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
93.77% below the market average93.77% below the market average93.77% below the market average93.77% below the market average93.77% below the market average
91.3% below the sector average91.3% below the sector average91.3% below the sector average91.3% below the sector average91.3% below the sector average
Price Trend
16.68% below the market average16.68% below the market average16.68% below the market average16.68% below the market average16.68% below the market average
24.44% above the sector average24.44% above the sector average24.44% above the sector average24.44% above the sector average24.44% above the sector average
Income
61.75% below the market average61.75% below the market average61.75% below the market average61.75% below the market average61.75% below the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average
Growth
86.34% above the market average86.34% above the market average86.34% above the market average86.34% above the market average86.34% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 14
Neutral 5
Sell 0
Strong Sell 0
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 20-Feb-25 08-Aug-24
Paid 24-Mar-25 09-Sep-24
Amount 210.00¢ 100.00¢

Trades for 06-Jun-2025

Time Volume / Share Price
13:53 0 @ 10,710.00p
13:53 5 @ 10,710.00p
13:53 44 @ 10,714.00p
13:53 42 @ 10,712.00p
13:53 4 @ 10,714.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page